Safety and efficacy of low-dose cyclosporine in association with everolimus to minimize renal dysfunction in heart transplant recipients.

Trial Profile

Safety and efficacy of low-dose cyclosporine in association with everolimus to minimize renal dysfunction in heart transplant recipients.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2012

At a glance

  • Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Mycophenolate mofetil (Primary)
  • Indications Heart transplant rejection
  • Focus Adverse reactions
  • Acronyms SHIRAKISS
  • Most Recent Events

    • 16 Apr 2011 2-year results presented at the 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 27 Jan 2010 Results reported in Transplantation.
    • 12 May 2009 Additional lead trial centre Alma Mater Studiorum University of Bologna identified, primary endpoint identified as GFR as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top